Upadacitinib and filgotinib: The role of JAK1 selective inhibition in the treatment of rheumatoid arthritis

Drugs in Context

Volumn 8, Issue , 2019, Pages

  Biggioggero, Martina ^a   Becciolini, Andrea ^a   Crotti, Chiara ^a   Agape, Elena ^b   Favalli, Ennio Giulio ^a  

^a ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Arthritis; Filgotinib; Janus kinase 1; Rheumatoid; Upadacitinib

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; FILGOTINIB; JANUS KINASE 1; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR; UPADACITINIB;

ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; CELL PROLIFERATION; DRUG EFFICACY; DRUG PROTEIN BINDING; ENZYME INHIBITION; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; IMMUNOMODULATION; LYMPHOCYTE; MORNING STIFFNESS; OLIGOMERIZATION; PAIN; POSTMARKETING SURVEILLANCE; PROTEIN PHOSPHORYLATION; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; VISUAL ANALOG SCALE;

EID: 85075743032     PISSN: 17451981     EISSN: 17404398     Source Type: Journal    
DOI: 10.7573/dic.212595     Document Type: Review

References (67)

1. Myasoedova E, Crowson CS, Kremers HM, et al. Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum. 2010;62(6):1576-1582. http://dx.doi.org/10.1002/art.27425
2. Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res. 2002;4(Suppl 3):S265-S272. http://dx.doi.org/10.1186/ar578
3. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-2219. http://dx.doi.org/10.1056/NEJMra1004965
4. Lefevre S, Knedla A, Tennie C, et al. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med. 2009;15(12):1414-1420. http://dx.doi.org/10.1038/nm.2050
5. Avina-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59(12):1690-1697. http://dx.doi.org/10.1002/art.24092
6. Firestein GS. The disease formerly known as rheumatoid arthritis. Arthritis Res Ther. 2014;16(3):114. http://dx.doi.org/10.1186/ar4593
7. Holmqvist M, Ljung L, Askling J. Mortality following new-onset rheumatoid arthritis: has modern rheumatology had an impact? Ann Rheum Dis. 2018;77(1):85-91. http://dx.doi.org/10.1136/annrheumdis-2017-212131
8. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3-15. http://dx.doi.org/10.1136/annrheumdis-2015-207524
9. Smolen JS, Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol. 2015;11(5):276-289. http://dx.doi.org/10.1038/nrrheum.2015.8
10. Favalli EG, Biggioggero M, Meroni PL. Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an "anchor" drug? Autoimmun Rev. 2014;13(11):1102-1108. http://dx.doi.org/10.1016/j.autrev.2014.08.026
11. Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001. http://dx.doi.org/10.1038/nrdp.2018.1
12. McInnes IB, Buckley CD, Isaacs JD. Cytokines in rheumatoid arthritis - shaping the immunological landscape. Nat Rev Rheumatol. 2016;12(1):63-68. http://dx.doi.org/10.1038/nrrheum.2015.171
13. Chighizola CB, Favalli EG, Meroni PL. Novel mechanisms of action of the biologicals in rheumatic diseases. Clin Rev Allergy Immunol. 2014;47(1):6-16. http://dx.doi.org/10.1007/s12016-013-8359-x
14. Smolen JS, Landewé R, Bijlsma J, et al. Eular recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960-977. http://dx.doi.org/10.1136/annrheumdis-2016-210715
15. Biggioggero M, Favalli EG. Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides. Drug Dev Res. 2014;75(Suppl 1):S38-S41. http://dx.doi.org/10.1002/ddr.21192
16. Favalli EG, Pregnolato F, Biggioggero M, et al. Twelve-year retention rate of first-line tumor necrosis factor inhibitors in rheumatoid arthritis: real-life data from a local registry. Arthritis Care Res (Hoboken). 2016;68(4):432-439. http://dx.doi.org/10.1002/acr.22788
17. Sarzi-Puttini P, Antivalle M, Marchesoni A, et al. Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN). Reumatismo. 2008;60(4):290-295. https://dx.doi.org/10.4081/reumatismo.2008.290
18. Iannone F, Sinigaglia L, Favalli EG, et al. Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability. Clin Rheumatol. 2016;35(11):2649-2656. http://dx.doi.org/10.1007/s10067-016-3349-z
19. Iannone F, Ferraccioli G, Sinigaglia L, et al. Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA. Clin Rheumatol. 2018;37(2):315-321. http://dx.doi.org/10.1007/s10067-017-3846-8
20. De Hair MJH, Jacobs JWG, Schoneveld JLM, et al. Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need. Rheumatology (Oxford). 2017. http://dx.doi.org/10.1093/rheumatology/kex349
21. Favalli EG, Bugatti S, Biggioggero M, et al. Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs. Biomed Res Int. 2014;2014:831603. http://dx.doi.org/10.1155/2014/831603
22. Cantini F, Niccoli L, Nannini C, et al. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthritis Rheum. 2016;45(5):519-532. http://dx.doi.org/10.1016/j.semarthrit.2015.10.001
23. Sebastiani M, Anelli MG, Atzeni F, et al. Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register. Joint Bone Spine. 2014;81(6):508-512. http://dx.doi.org/10.1016/j.jbspin.2014.06.011
24. Cantini F, Niccoli L, Nannini C, et al. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Semin Arthritis Rheum. 2017;47(2):183-192. http://dx.doi.org/10.1016/j.semarthrit.2017.03.008
25. Favalli EG, Biggioggero M, Marchesoni A, et al. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology (Oxford). 2014;53(9):1664-1668. http://dx.doi.org/10.1093/rheumatology/keu158
26. Todoerti M, Favalli EG, Iannone F, et al. Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus. Rheumatology (Oxford). 2018;57(Suppl 7):vii42-vii53. http://dx.doi.org/10.1093/rheumatology/key195
27. Favalli EG, Raimondo MG, Becciolini A, et al. The management of first-line biologic therapy failures in rheumatoid arthritis: current practice and future perspectives. Autoimmun Rev. 2017;16(12):1185-1195. http://dx.doi.org/10.1016/j.autrev.2017.10.002
28. Ferguson FM, Gray NS. Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 2018;17(5):353-377. http://dx.doi.org/10.1038/nrd.2018.21
29. Schwartz DM, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25-36. http://dx.doi.org/10.1038/nrrheum.2015.167
30. Hirahara K, Schwartz D, Gadina M, et al. Targeting cytokine signaling in autoimmunity: back to the future and beyond. Curr Opin Immunol. 2016;43:89-97. http://dx.doi.org/10.1016/j.coi.2016.10.001
31. Taylor PC. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019;58(Suppl 1):i17-i26. http://dx.doi.org/10.1093/rheumatology/key225
32. Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014;57(12):5023-5038. http://dx.doi.org/10.1021/jm401490p
33. Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374(13):1243-1252. http://dx.doi.org/10.1056/NEJMoa1507247
34. Yamaoka K. Janus kinase inhibitors for rheumatoid arthritis. Curr Opin Chem Biol. 2016;32:29-33. http://dx.doi.org/10.1016/j.cbpa.2016.03.006
35. Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;17(1):78. http://dx.doi.org/10.1038/nrd.2017.267
36. Liongue C, Ward AC. Evolution of the JAK-STAT pathway. JAKSTAT. 2013;2(1):e22756. http://dx.doi.org/10.4161/jkst.22756
37. O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368(2):161-170. http://dx.doi.org/10.1056/NEJMra1202117
38. O'Shea JJ, Kontzias A, Yamaoka K, et al. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013;72(Suppl 2): ii111-ii115. http://dx.doi.org/10.1136/annrheumdis-2012-202576
39. Hofmann SR, Ettinger R, Zhou YJ, et al. Cytokines and their role in lymphoid development, differentiation and homeostasis. Curr Opin Allergy Clin Immunol. 2002;2(6):495-506. http://dx.doi.org/10.1097/01.all.0000044534.45448.bf
40. Malemud CJ. Negative regulators of JAK/STAT signaling in rheumatoid arthritis and osteoarthritis. Int J Mol Sci. 2017;18(3). http://dx.doi.org/10.3390/ijms18030484
41. Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (cp-690,550). J Immunol. 2011;186(7):4234-4243. http://dx.doi.org/10.4049/jimmunol.1003668
42. O'Shea JJ, Schwartz DM, Villarino AV, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311-328. http://dx.doi.org/10.1146/annurev-med-051113-024537
43. Raimondo MG, Biggioggero M, Crotti C, et al. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Des Devel Ther. 2017;11:1593-1603. http://dx.doi.org/10.2147/DDDT.S100302
44. Biggioggero M, Crotti C, Becciolini A, et al. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. Drug Des Devel Ther. 2019;13:57-70. http://dx.doi.org/10.2147/DDDT.S150580
45. Norman P. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014;23(8):1067-1077. http://dx.doi.org/10.1517/13543784.2014.918604
46. Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (select-next): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10139):2503-2512. http://dx.doi.org/10.1016/S0140-6736(18)31115-2
47. Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (select-beyond): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391(10139):2513-2524. http://dx.doi.org/10.1016/S0140-6736(18)31116-4
48. Van Vollenhoven R, Takeuchi T, Pangan AL, et al. A phase 3, randomized, controlled trial comparing upadacitinib monotherapy to MTX monotherapy in MTX-naïve patients with active rheumatoid arthritis. Arthritis Rheumatol. 2018;70(Suppl 10).
49. Smolen JS, Cohen S, Emery P, et al. Upadacitinib as monotherapy: a phase 3 randomized controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate. Arthritis Rheumatol. 2018; 70(Suppl 10).
50. Fleischmann R, Pangan AL, Mysler E, et al. A phase 3, randomized, double-blind study comparing upadacitinib to placebo and to adalimumab, in patients with active rheumatoid arthritis with inadequate response to methotrexate. Arthritis Rheumatol. 2018;70(Suppl 10).
51. Crotti C, Biggioggero M, Becciolini A, et al. Sarilumab: patient-reported outcomes in rheumatoid arthritis. Patient Related Outcome Measures. 2018;9:275-284.
52. Strand V, Buch M, Tundia N, et al. Upadacitinib monotherapy improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to methotrexate. Arthritis Rheumatol. 2018;70(Suppl 10).
53. Westhovens R, Taylor PC, Alten R, et al. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis. 2017;76(6):998-1008. http://dx.doi.org/10.1136/annrheumdis-2016-210104
54. Kavanaugh A, Kremer J, Ponce L, et al. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis. 2017;76(6):1009-1019. http://dx.doi.org/10.1136/annrheumdis-2016-210105
55. Genovese M, Westhovens R, Meuleners L, et al. Effect of filgotinib, a selective JAK1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes. Arthritis Res Ther. 2018;20(1):57. http://dx.doi.org/10.1186/s13075-018-1541-z
56. Genovese MC, Kalunian KC, Walker D, et al. Safety and efficacy of filgotinib in a phase 3 trial of patients with active rheumatoid arthritis and inadequate response or intolerance to biologic dmards. Arthritis Rheumatol. 2018;70(Suppl 10).
57. Kavanaugh A, Genovese MC, Winthrop K, et al. Rheumatoid arthritis treatment with filgotinib: week 132 safety data from a phase 2b open-label extension study. Arthritis Rheumatol. 2018;70(Suppl 10).
58. Cohen S, Curtis JR, DeMasi R, et al. Worldwide, 3-year, post-marketing surveillance experience with tofacitinib in rheumatoid arthritis. Rheumatol Ther. 2018;5(1):283-291. http://dx.doi.org/10.1007/s40744-018-0097-3
59. Caporali R, Zavaglia D. Real-world experience with tofacitinib for treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2019;37(3):485-495.
60. Cohen S, Radominski SC, Gomez-Reino JJ, et al. Analysis of infections and all-cause mortality in phase ii, phase iii, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66(11):2924-2937. http://dx.doi.org/10.1002/art.38779
61. O'Shea JJ, Laurence A, McInnes IB. Back to the future: oral targeted therapy for ra and other autoimmune diseases. Nat Rev Rheumatol. 2013;9(3):173-182. http://dx.doi.org/10.1038/nrrheum.2013.7
62. Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13(4):234-243. http://dx.doi.org/10.1038/nrrheum.2017.23
63. Park SO, Wamsley HL, Bae K, et al. Conditional deletion of jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for jak2 inhibition in humans. PLoS One. 2013;8(3):e59675. http://dx.doi.org/10.1371/journal.pone.0059675
64. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-2038. http://dx.doi.org/10.1016/s0140-6736(16)30173-8
65. Md Yusof MY, Emery P. Targeting interleukin-6 in rheumatoid arthritis. Drugs. 2013;73(4):341-356. http://dx.doi.org/10.1007/s40265-013-0018-2
66. Smitten AL, Choi HK, Hochberg MC, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the united states and the united kingdom. Arthritis Rheum. 2007;57(8):1431-1438. http://dx.doi.org/10.1002/art.23112
67. Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66(10):2675-2684. http://dx.doi.org/10.1002/art.38745